Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05897099 · ClinicalTrials.gov registry record · NA

Comprehensive HIV and Harm Prevention Via Telehealth

A NA study of HIV Infections, sponsored by University of Miami.

Recruiting
Registry status
NA
Development phase
350
Enrollment target
2
Study locations

NCT05897099 is a NA study of HIV Infections that is actively recruiting participants, run by University of Miami. The registered enrollment target is 350 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05897099, a NA study of HIV Infections, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
NA
Development phase
350 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

Conditions Studied

Interventions

  • BEHAVIORAL Comprehensive Tele-harm Reduction
  • BEHAVIORAL Off-site Linkage to HIV Prevention

Study Locations (2)

Florida

  • IDEA Miami - Miami
  • IDEA Syringe Services Program - Miami

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2024-10-07
Est. Completion 2028-05-31
Phase NA

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT05897099

The ClinicalTrials.gov registry entry for NCT05897099 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (21% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Comprehensive Tele-harm Reduction is the first listed.

NCT05897099 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05897099 about?

NCT05897099 is a clinical study titled "Comprehensive HIV and Harm Prevention Via Telehealth". The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

What is the current status of trial NCT05897099?

This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2024-10-07. Estimated completion is 2028-05-31.

What conditions does trial NCT05897099 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT05897099?

The interventions under investigation include: Comprehensive Tele-harm Reduction (BEHAVIORAL), Off-site Linkage to HIV Prevention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05897099?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05897099 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.